In colorectal cancer, PROX1 has been identified as a downstream target of the TCF/beta-catenin signaling pathway [30], and its lower expression in colon cancer cells was connected with estrogen receptor beta signaling [81]. Here, PROX1 is linked to colonic neoplasm.